Che-Kai Tsao, MD, discusses key updates from the phase 3 CheckMate 9ER trial, and how these data clarify the role of nivolumab plus cabozantinib as a new standard of care in renal cell carcinoma.
Che-Kai Tsao, MD
Advertisement
Articles by Che-Kai Tsao, MD
Che-Kai Tsao, MD, discusses the investigation of cabozantinib in combination with nivolumab and ipilimumab in patients with renal cell carcinoma.
Che-Kai Tsao, MD, discusses first-line treatment approaches for patients with clear cell renal cell carcinoma.
Che-Kai Tsao, MD, shares strategies to improve outcomes in renal cell carcinoma.
Che-Kai Tsao, MD, shares strategies to improve outcomes in renal cell carcinoma.
Che-Kai Tsao, MD, discusses the rationale behind staging disease, especially in the context of when patients are diagnosed with renal cell carcinoma.
Advertisement
Latest Updated Articles
Dr. Tsao on Improving Outcomes in RCCPublished: May 15th 2020 | Updated:
Dr. Tsao on Rationale for Staging Renal Cell CarcinomaPublished: March 10th 2020 | Updated:
- Dr. Tsao on Improving Outcomes in RCC
Published: May 16th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5